Search results

Jump to: navigation, search
  • ...st, with a Ki of 3.4nM and selectivity of around 200x for CB2 over [[CB1]] receptors. It was discovered by, and named after, John W. Huffman. ...antiinflamatory action is induced through agonist action at [[cannabinoid receptors]], which prevents microglial activation that elicits the inflammation. Addi
    1 KB (214 words) - 03:51, 15 February 2015
  • ...nding affinity in vitro for both the [[CB1]] and [[CB2 receptor]]s, with a CB2 affinity of 0.91nM and 13x selectivity over the CB1 receptor. In animal stu
    752 B (118 words) - 03:59, 15 February 2015
  • ...e it was reported to have high affinity for both CB1 (Ki = 5.5 nM) and CB2 receptors (Ki = 0.48 nM).[1] AB-005 features groups found in other previously reporte
    1 KB (141 words) - 04:01, 15 February 2015
  • ...th the [[CB1]] and [[CB2 receptor]]s, with a Ki of 11nM at CB1 and 33nM at CB2. Unlike many of the older JWH series compounds, this compound does not have
    1 KB (180 words) - 04:15, 15 February 2015
  • ...an EC50 for [[CB1]] activation of 19nM, and 7x selectivity for CB1 over [[CB2]]. It was discovered during research into the related compound [[SDB-001]]
    353 B (53 words) - 04:27, 15 February 2015
  • ...nnabinoids (natural cannabinoids). The principal endogenous ligand for the CB2 receptor is 2-arachidonoylglycerol (2-AG). CB2 was cloned in 1993 by a research group from Cambridge looking for a second
    11 KB (1,520 words) - 12:12, 23 February 2015
  • == Cannabinoid receptors == ...noid receptor]] research. With the discovery of the endogenous cannabinoid receptors, some recent scientific literature has focused on the effects of phytocanna
    24 KB (3,496 words) - 12:15, 23 February 2015
  • ...chers began to study and better understand how cannabinoids acted on these receptors. THC is associated – more than any other cannabinoid – with most of the ...ent of medical cannabis; it is a nonpsychotropic and how it works on brain receptors is not known. CBD represents up to 40% of extracts of Cannabis sativa. A 20
    26 KB (3,891 words) - 14:16, 23 February 2015
  • ...nce agonist HU-210. It is a potent agonist at both the [[CB1]] and [[CB2]] receptors, with a binding affinity of 0.041nM at the CB1 receptor, making it marginal
    435 B (67 words) - 04:26, 13 February 2015
  • ...nding studies to determine the structure and function of the [[cannabinoid receptors]], but has been made illegal in some countries due to its possible abuse po
    580 B (84 words) - 04:29, 13 February 2015
  • ...e [[CB1]] and [[CB2]] [[cannabinoid receptors]], with some selectivity for CB2. It produces effects in animals similar to those of [[THC]], a [[cannabinoi ...annabinoid (CB1) receptor five times greater than that of THC. Cannabinoid receptors are found in mammalian brain and spleen tissue; however, the structural det
    9 KB (1,244 words) - 06:53, 14 February 2015
  • ...be important in determining affinity and efficacy at both the CB1 and CB2 receptors, and has led to the development of a large number of related derivatives.
    770 B (125 words) - 06:59, 14 February 2015
  • ...ill show significant affinity and efficacy at both receptors despite being CB2 selective overall.
    996 B (137 words) - 07:28, 14 February 2015
  • ...abinoid]] ligands, with an adamantoyl group, generally confers significant CB2 selectivity, but reasonable CB1 affinity and selectivity is retained when a
    803 B (106 words) - 07:38, 14 February 2015
  • ...that acts as a potent agonist for the cannabinoid receptors [[CB1]] and [[CB2]] with a Ki of 24.2nM and a EC50 of 359nM at CB1. It is a 3-(tetramethylcyc
    1 KB (216 words) - 07:46, 14 February 2015
  • ...-001 revealed that it acts as a full agonist at CB1 (EC50 = 35 nM) and CB2 receptors (EC50 = 48 nM). However, AB-001 was found to possess only weak cannabimimet
    1 KB (153 words) - 07:52, 14 February 2015
  • ...ntiomer. It was developed as a selective radioligand for the [[cannabinoid receptors]] and has been used as its 131I derivative for mapping the distribution of
    623 B (95 words) - 17:21, 14 February 2015
  • ...ansferase, an effect that appears to be independent from its action on CB2 receptors.
    695 B (111 words) - 16:36, 14 February 2015
  • ...annabinoid receptors]], with Ki values of 0.9nM at [[CB1]] and 23.2nM at[[ CB2]]. It was originally developed by Pfizer in 2009 as an analgesic medication
    700 B (96 words) - 16:44, 14 February 2015
  • ...h the usual trend of 2-methyl derivatives having increased selectivity for CB2 (cf. [[JWH-018]] vs [[JWH-007]], [[JWH-081]] vs [[JWH-098]]).
    1 KB (181 words) - 04:25, 14 April 2015

View (previous 20 | next 20) (20 | 50 | 100 | 250 | 500)